The Clinical Application Value of Urinary NMP22/Cr Ratio in Clinical Diagnosis and Treatment of Bladder Cancer in Primary Medical Units
Objective To analyze the clinical value of urinary nuclear matrix protein 22(NMP22)/creatinine(Cr)ratio in the diagnosis of bladder cancer.Methods The study cohort comprised three groups:the bladder cancer group,which included 221 ases of non-muscle-invasive bladder cancer and 44 cases of muscle-invasive bladder cancer;the stone group,consisting of 90 cases of urinary system stones;and a control group of 50 healthy volunteers who underwent physical examinations.Urinary levels of NMP22 and creatinine(Cr)were measured across all groups.Receiver operating characteristic(ROC)curves were employed to evaluate the diagnostic efficacy of these biomarkers in bladder cancer detection.Results The ratio of NMP22/Cr in urine of patients with bladder cancer was significantly higher than that of patients with non cancerous diseases(P＜0.001)and healthy controls(P＜0.001).The level of NMP22/Cr is significantly correlated with pathological T staging(P＜0.001)and grading(P＜0.001).The AUC of bladder cancer diagnosed by NMP22/Cr was 0.808(95％CI:0.767-0.849).When the cut-off value of NMP22/Cr is 19.55 ng·mg-1,the sensitivity is 64.2％and the specificity is 93.6％.Conclusion Urine NMP22/Cr detection can improve the diagnostic efficiency of bladder cancer,and can be an important auxiliary examination for clinical diagnosis of bladder cancer in grass-roots units.
万方数据
维普
